Nektar Therapeutics Stock Forum

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nektar Therapeutics (NKTR) presented preclinical data for NKTR-422, a novel modified CSF protein, at the 2024 ACR conference. The drug demonstrated promising results in inflammation resolution and tissue repair across multiple preclinical models. NKTR-422functions by targeting anti-inflammatory tissue resident macrop...

$Nektar Therapeutics (NKTR.US)$
Target price $7

$Nektar Therapeutics (NKTR.US)$
SAN FRANCISCO, Nov. 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and...

$Nektar Therapeutics (NKTR.US)$ common go to 1,50

$Nektar Therapeutics (NKTR.US)$
SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO).
Rezpegal...

$Nektar Therapeutics (NKTR.US)$ Data From Nektar's Multiple Phase 1b Studies In Inflammatory Skin Conditions Demonstrate Durable Dose-dependent Improvements In Physician-assessed Disease Activity And Patient-reported Outcomes
Benzinga· 1 min ago
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated ...

$Nektar Therapeutics (NKTR.US)$ m
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
Nektar Therapeutics (NKTR) published peer-reviewed data from two Phase 1b studies in Nature Communications showing promising results for rezpegaldesleukin in treating atopic dermatitis (AD) and psoriasis (PsO). The studies demonstrated that the drug safely increased regulatory T cells (Tregs) and improved disease outcom...